This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

By Jonathan Gardner • Oct. 2, 2026

Lilly, Foghorn part ways; Wave’s FDA-approved plans

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

By Gwendolyn Wu • Oct. 1, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. 

By Jonathan Gardner • Sept. 30, 2026

PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

By Ben Fidler • Sept. 30, 2026

An AI agent made a tiny drug R&D mistake. Then it kept going.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

By Sy Mukherjee • Sept. 30, 2026

Beam sues 2 biotechs, alleging theft of base editing trade secrets

Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

By Gwendolyn Wu • Sept. 29, 2026

Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

By Jonathan Gardner • Sept. 29, 2026

UniQure tumbles with latest data for Huntington’s gene therapy

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."

By Jacob Bell • Sept. 29, 2026

ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’

Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.

By Gwendolyn Wu • Sept. 29, 2026

AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

By Ben Fidler • Sept. 29, 2026

Kodiak skyrockets on positive study data for 2 eye drugs

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

By Jonathan Gardner • Sept. 28, 2026

This week in charts: Novo’s rise and fall and AI biotechs’ big haul

The latest installment in BioPharma Dive’s data visualization series features a closer look at Novo's stock performance and the recent run of fundraising success for AI drug discovery startups.

By Gwendolyn Wu • Sept. 25, 2026

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

By Ben Fidler • Sept. 25, 2026

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

By Gwendolyn Wu • Sept. 24, 2026

Lilly’s latest China drug deal; Immunovant’s setback in lupus

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

By Ben Fidler • Sept. 24, 2026

Enveda, an AI drugmaker, banks $311M in venture funding

Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.

By Gwendolyn Wu • Sept. 23, 2026

9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe

Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”

By Kristin Jensen • Sept. 23, 2026

Viking shares surge on updated obesity drug data

Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

By Jonathan Gardner • Sept. 22, 2026

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

By Ben Fidler • Sept. 22, 2026

Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’

Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.

By Ben Fidler • Sept. 21, 2026

How J&J paved the way for Compass’ coming psychedelic drug launch

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.

By Jacob Bell • Sept. 21, 2026

Xenon shares fall following depression trial pause

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

By Jonathan Gardner • Sept. 18, 2026

This week in charts: GSK’s China deals, the $300M IPO club and selling the news

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.

By Ben Fidler • Sept. 18, 2026

Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

By BioPharma Dive staff • Sept. 18, 2026

Electra amasses $350M in biotech’s latest big IPO

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

By Gwendolyn Wu • Sept. 17, 2026